Renascience Inc. (TYO:4889)
Japan · Delayed Price · Currency is JPY 1,469.00
+14.00 (0.96%)
At close: Feb 6, 2026
Renascience Revenue
Renascience had revenue of 87.00M JPY in the twelve months ending September 30, 2025, down -32.56% year-over-year. In the fiscal year ending March 31, 2025, Renascience had annual revenue of 132.00M, down -31.96%.
Revenue (ttm)
87.00M
Revenue Growth
-32.56%
P/S Ratio
223.73
Revenue / Employee
29.00M
Employees
3
Market Cap
19.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 132.00M | -62.00M | -31.96% |
| Mar 31, 2024 | 194.00M | 94.00M | 94.00% |
| Mar 31, 2023 | 100.00M | -39.00M | -28.06% |
| Mar 31, 2022 | 139.00M | -70.00M | -33.49% |
| Mar 31, 2021 | 209.00M | 137.00M | 190.28% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kidswell Bio | 6.61B |
| RaQualia Pharma | 3.05B |
| ReproCELL | 2.63B |
| Japan Tissue Engineering | 2.26B |
| Immuno-Biological Laboratories | 1.01B |
| Stella Pharma | 992.00M |
| AnGes | 818.00M |
| CellSeed | 161.00M |